Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3655 Nobel Dr Ste 260 SAN DIEGO CA 92122-1050 |
Tel: | N/A |
Website: | https://www.darebioscience.com |
IR: | See website |
Key People | ||
Sabrina Martucci Johnson President, Chief Executive Officer, Principal Financial Officer, Company Secretary, Director | John Fair Chief Commercial Officer |
Business Overview |
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. |
Financial Overview |
For the fiscal year ended 31 December 2023, Dare Bioscience Inc revenues decreased 72% to $2.8M. Net loss decreased 3% to $30.2M. Revenues reflect License fee revenue decrease of 90% to $1M. Lower net loss reflects Research and development expenses decrease of 29% to $20.7M (expense), Other income increase of 78% to $778K (income), Operating lease cost decrease of less than 1% to $600K (expense). |
Employees: | 23 as of Mar 27, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $18.29M as of Dec 31, 2023 |
Annual revenue (TTM): | $2.81M as of Dec 31, 2023 |
EBITDA (TTM): | -$30.90M as of Dec 31, 2023 |
Net annual income (TTM): | -$30.16M as of Dec 31, 2023 |
Free cash flow (TTM): | -$39.49M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 100,581,900 as of Mar 27, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |